# Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

> **NCT01013506** · PHASE2 · WITHDRAWN · sponsor: **Vanderbilt-Ingram Cancer Center**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** IGF-1R inhibitor OSI-906
- **DRUG:** erlotinib hydrochloride
- **DRUG:** goserelin
- **DRUG:** letrozole

## Key facts

- **NCT ID:** NCT01013506
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-08
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was abandoned before opening to accrual. Replaced by another study.
- **Last updated:** 2013-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01013506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01013506, "Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT01013506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*